51
|
Abstract
Progress in understanding and treating metastatic melanoma is the result of decades of basic and translational research as well as the development of better in vitro tools for modeling the disease. Here, we review the latest therapeutic options for metastatic melanoma and the known genetic and non-genetic mechanisms of resistance to these therapies, as well as the in vitro toolbox that has provided the greatest insights into melanoma progression. These include next-generation sequencing technologies and more complex 2D and 3D cell culture models to functionally test the data generated by genomics approaches. The combination of hypothesis generating and hypothesis testing paradigms reviewed here will be the foundation for the next phase of metastatic melanoma therapies in the coming years.
Collapse
|
52
|
Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. Biomaterials 2017; 145:233-241. [PMID: 28888113 DOI: 10.1016/j.biomaterials.2017.08.041] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2017] [Revised: 08/25/2017] [Accepted: 08/28/2017] [Indexed: 11/22/2022]
Abstract
The tumour microenvironment is critical to both the initiation and maintenance of tumorigenesis. Reconstitution of the microenvironment is a major challenge for in vitro cancer models. Indeed, conventional 2D culture systems cannot replicate the complexity, diversity and dynamic nature of the tumour microenvironment. In this study, we have developed a 3D endotheliazed vesical equivalent by using tissue engineering from primary human cells in which non-invasive or invasive bladder cancer (BCa) cell lines, cultured as compact spheroids, were incorporated. Invasive BCa cells cross the basement membrane and invade the stromal compartment whereas non-invasive BCa cells are confined to the urothelium. Our 3D BCa model could be used as a reliable model for assessing drug responses, potentially reducing or partially replacing animal experiments, and thus should have applications in the identification of novel targets as well as toxicological evaluation of anti-cancer therapies.
Collapse
|
53
|
Vig K, Chaudhari A, Tripathi S, Dixit S, Sahu R, Pillai S, Dennis VA, Singh SR. Advances in Skin Regeneration Using Tissue Engineering. Int J Mol Sci 2017; 18:E789. [PMID: 28387714 PMCID: PMC5412373 DOI: 10.3390/ijms18040789] [Citation(s) in RCA: 362] [Impact Index Per Article: 51.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 03/04/2017] [Indexed: 12/11/2022] Open
Abstract
Tissue engineered skin substitutes for wound healing have evolved tremendously over the last couple of years. New advances have been made toward developing skin substitutes made up of artificial and natural materials. Engineered skin substitutes are developed from acellular materials or can be synthesized from autologous, allograft, xenogenic, or synthetic sources. Each of these engineered skin substitutes has their advantages and disadvantages. However, to this date, a complete functional skin substitute is not available, and research is continuing to develop a competent full thickness skin substitute product that can vascularize rapidly. There is also a need to redesign the currently available substitutes to make them user friendly, commercially affordable, and viable with longer shelf life. The present review focuses on providing an overview of advances in the field of tissue engineered skin substitute development, the availability of various types, and their application.
Collapse
Affiliation(s)
- Komal Vig
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Atul Chaudhari
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Shweta Tripathi
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Saurabh Dixit
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Rajnish Sahu
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Shreekumar Pillai
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Vida A Dennis
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| | - Shree R Singh
- Center for Nanobiotechnology Research, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, USA.
| |
Collapse
|
54
|
Bergers LIJC, Reijnders CMA, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, Gibbs S. Immune-competent human skin disease models. Drug Discov Today 2016; 21:1479-1488. [PMID: 27265772 DOI: 10.1016/j.drudis.2016.05.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 04/13/2016] [Accepted: 05/12/2016] [Indexed: 12/29/2022]
Abstract
All skin diseases have an underlying immune component. Owing to differences in animal and human immunology, the majority of drugs fail in the preclinical or clinical testing phases. Therefore animal alternative methods that incorporate human immunology into in vitro skin disease models are required to move the field forward. This review summarizes the progress, using examples from fibrosis, autoimmune diseases, psoriasis, cancer and contact allergy. The emphasis is on co-cultures and 3D organotypic models. Our conclusion is that current models are inadequate and future developments with immune-competent skin-on-chip models based on induced pluripotent stem cells could provide a next generation of skin models for drug discovery and testing.
Collapse
Affiliation(s)
| | | | | | - Sander W Spiekstra
- Department of Dermatology, VU University Medical Center, Amsterdam, The Netherlands
| | - Tanja D de Gruijl
- Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
| | - Ester M Weijers
- Department of Dermatology, VU University Medical Center, Amsterdam, The Netherlands
| | - Susan Gibbs
- Department of Dermatology, VU University Medical Center, Amsterdam, The Netherlands; Department of Oral Cell Biology, Academic Center for Dentistry Amsterdam, University of Amsterdam and VU University, Amsterdam, The Netherlands.
| |
Collapse
|